We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the Relationships Between Refractory Hypertension, Overweight/Obesity and Sleep Apnea Syndrome (RHOOSAS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00746902
First Posted: September 4, 2008
Last Update Posted: November 7, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Fondation de Recherche sur l'Hypertension Artérielle
Information provided by (Responsible Party):
University Hospital, Grenoble
September 3, 2008
September 4, 2008
November 7, 2014
June 2008
December 2013   (Final data collection date for primary outcome measure)
leptinemia [ Time Frame: inclusion visit, visit month 3, visit month 6 or 9 ]
Same as current
Complete list of historical versions of study NCT00746902 on ClinicalTrials.gov Archive Site
BP readings (clinical and ABPM), metabolic parameters (lipids, glycaemia, adiponectin) and sympathetic nervous system effectors (adrenaline, noradrenaline and metanephrines). [ Time Frame: inclusion visit, visit month 3, visit month 6 or 9 ]
Same as current
Not Provided
Not Provided
 
Study of the Relationships Between Refractory Hypertension, Overweight/Obesity and Sleep Apnea Syndrome
Study of the Relationships Between Refractory Hypertension, Overweight/Obesity and Sleep Apnea Syndrome

The purpose of the study is to investigate the links between blood pressure (BP), overweight or obesity, and sleep apnea syndrome (SAS), by studying a large cohort of subjects suffering from refractory hypertension.

Primary objective

  • To compare plasmatic leptin levels in patients suffering from refractory hypertension depending on whether or not they experience SAS.

Secondary objectives

  • To ascertain what determines the difference in plasmatic leptin concentrations in patients suffering from refractory hypertension depending on whether or not they experience SAS.
  • To characterise BP readings (from clinical and ambulatory (ABPM) measurements) in patients suffering from refractory hypertension depending on whether or not they experience SAS.
  • To characterise metabolic parameters (lipids, glycaemia, adiponectin) and sympathetic nervous system effectors (adrenaline, noradrenaline and metanephrines) in patients suffering from refractory hypertension depending on whether or not they experience SAS.
  • To characterise BP readings, metabolic parameters and sympathetic nervous system effectors in patients suffering from refractory hypertension according to the severity of the SAS (in those who experience this problem).
  • To study, in patients with both SAS and refractory hypertension, the impact of nasal continuous positive airway pressure (CPAP) treatment on BP readings, metabolic parameters and sympathetic nervous system effectors, by comparing those who are compliant with the CPAP regimen with those who are non-compliant.

A number of factors predispose subjects to both hypertension and SAS, including overweight/obesity and hyperinsulinism. The pathogenesis of concomitant overweight/obesity and hypertension is multifactorial. There is an independent relationship between the degree of insulin resistance and the severity of SAS. A number of studies have suggested that hormones secreted by adipose tissue are involved in the pathogenesis of both hypertension and SAS, and overweight/obesity has been shown to be associated with elevated leptin levels coupled with reduced adiponectin levels.

Leptin is produced in adipose tissue and its levels rise with overweight/obesity due to peripheral resistance to its action. A number of studies have detected high leptinemia in both hypertensives and people suffering from SAS. Leptin may activate the sympathetic nervous system and promote SAS-related hypertension.

Adiponectin which is also produced in adipose tissue has beneficial activities, notably on atherogenesis. A relationship between hypertension and adiponectin has yet to be demonstrated.

Unlike leptin, adiponectin levels do not seem to be elevated in patients with SAS.

In terms of treatment, a number of studies have shown that CPAP has a positive effect on BP readings. Although this effect is modest, it is greater in subjects with SAS and rises with the severity of this condition. The effects of CPAP on plasmatic leptin and adiponectin levels are as yet unknown.

Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Refractory Hypertension
Device: nCPAP
Active nCPAP
  • Active Comparator: 1
    Arm 1: Active CPAP, a nasal continuous positive airway pressure
    Intervention: Device: nCPAP
  • Sham Comparator: 2
    Arm 2 : Sham CPAP :Placebo/CPAP
    Intervention: Device: nCPAP
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
62
September 2014
December 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients of either gender, of between 18 and 70
  • Suffering from refractory hypertension as defined by persistent clinical hypertension (> 140/90 mm Hg according to two different readings 24 hours apart) despite at least three classes of antihypertensive drugs (including a thiazide diuretic) at appropriate doses.
  • Recruited in the Cardiology Departments of the University Hospitals in Grenoble, Toulouse, Marseille and Poitiers, and in the Mozart Clinic in Paris.
  • Outpatients
  • Patients who have signed the consent form
  • Patients affiliated to or beneficiary of the social security system

Exclusion Criteria:

  • Failure to fulfil the inclusion criteria
  • Treated SAS, whatever the form of the treatment
  • Disease which might affect BP regulation, including Parkinson's disease, kidney or heart transplantation, dysautonomia, severe heart failure
  • Atrial fibrillation or regular extrasystole (> 10/minute)
  • Night- or shift-work
  • Pregnant and breast-feeding women
  • Patients under legal guardianship
  • Incarcerated patients or adults protected by the law
  • Hospitalised patients
  • Ongoing participation in another clinical research study
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT00746902
0803
2008-A00292-53 ( Registry Identifier: ID RCB )
No
Not Provided
Not Provided
University Hospital, Grenoble
University Hospital, Grenoble
Fondation de Recherche sur l'Hypertension Artérielle
Principal Investigator: Jean-Philippe BAGUET, Professor University Hospital, Grenoble
University Hospital, Grenoble
November 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP